ImmunoSite Technologies Automation Services are concentrated on fulfilling the special needs of life science industries.  Turnkey custom  integrated solutions using best-of-breed liquid handlers and integrated components are developed according to the ISO standards product realization requirements, and delivered to clients only after the systems pass rigorous biological acceptance testing.  ImmunoSite scientists and engineers perform all development and testing in ImmunoSite’s state of the art laboratory facilities with the client’s particular processes and samples.

“Since the formation of ImmunoSite in 2009, product quality and client satisfaction have been the most important goals.  Our proactive decision to become certified for both ISO 9001:2015 and ISO 13485:2016  anticipates the demands of our global customers and formalizes our continuing commitment to provide additional metrics for high quality products and services,” stated Dr. Carlos Aparicio, CEO Immunosite Technologies.

Biomarker data from Astra Zeneca demonstrates that biomarkers enhance success in every aspect (safety, dosing, efficacy, patient selection) of every state of the drug development process.  The huge investment in a new testing paradigm to address the new types of therapeutics was worth it for AZ, and will benefit not only all companies in the pharmaceutical industry, but mankind since we can expect to see an increase in the number of efficacious therapies sooner rather than later!

Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework.  David Cook,Dearg Brown, Robert Alexander, Ruth March, Paul Morgan, Gemma Satterthwaite & Menelas N. Pangalos.  Nature Reviews Drug Discovery (2014).  DOI: doi:10.1038/nrd4309. Published online 16 May 2014

ImmunoSite Technologies, LLC (IST), a provider of automation, design and customization of complex biological assays to biotechnology and pharmaceutical industries worldwide, announced its relocation to a newly expanded facility at 2831 Corporate Way in Miramar.  With the expansion, the company will be retaining its current employees, making a capital investment of $150,000 and adding 5 new jobs that will focus on product development.

CEO and President of ImmunoSite Technologies, LLC, Carlos Aparicio, Ph.D., who has almost 20 years experience in technical and scientific leadership in the pharmaceutical and medical devices industries, said, “ImmunoSite is perfectly positioned to support our clients’ increasing needs for worldwide automation and standardization of biological assays.  As a result, we committed to expand our headquarters to a new location in the Miramar Park of Commerce, Miramar, FL, in December 2012, where we could accommodate the increased scientific and administrative staff and the large robotic systems.”

City of Miramar Mayor Lori Moseley stated, “The city is pleased to welcome ImmunoSite Technologies to our community and is excited that their biotechnology expertise further diversifies our corporate base. It is our pleasure to have provided an expedited permitting process for the company which allowed it to become operational within a month’s time.”

“The expansion of ImmunoSite Technologies and other life science firms are the real success stories of Broward County,” said Mason Jackson, president and CEO of WorkForce One Employment Solutions.   “WorkForce One looks forward to growing this business sector by continuing to work with ImmunoSite through the recruitment and training process of their employees.”

“Floridian Community Bank partnered with ImmunoSite Technologies on their move to Miramar and expansion efforts by providing working capital financing to the company.  We are impressed with the quality of management and excited about future opportunities to continue funding the growth of ImmunoSite,” commented Scott Toth, commercial market manager for Floridian Community Bank.

Greater Fort Lauderdale Alliance president and CEO Bob Swindell added, “We are very happy that ImmunoSite Technologies is expanding in Miramar. The company’s decision to expand in Miramar is a good indicator that our efforts in growing South Florida’s strong life science cluster continue to pay off. We thank the Alliance’s Business Retention and Visitation Outreach (B.R.A.V.O) action team for working with the company through one-on-one meetings.”

For more information on ImmunoSite Technologies, please visit http://immunositetechnologies.com/

Call IST to discuss your automation needs at (888) 770-4478

Fort Lauderdale, Fla. – October 18, 2011 – ImmunoSite Technologies (IST), LLC, a leading provider of immune monitoring services, has helped to develop a Cell Culture Workshop that is offered  at the Employ Florida Banner Center for Life Sciences, based at Palm Beach State College’s Eissey Campus in Palm Beach Gardens.

Funded by Workforce Florida, Inc., the Banner Center for Life Sciences focuses on training and curriculum development in the life sciences industry and its biotechnology, pharmaceutical and medical device subsectors. It is unique in that the development of curricula is guided by an industry advisory council, and is based on current industry standards and needs for incumbent and future employees.

“The education of Florida’s workforce is vital for the growth of the life science industry in the state,” said Julie Wilkinson, Director of Pharma Services and Chief Information Officer of IST. “It’s been a great opportunity for IST to be associated with such a progressive program, and we look forward to continued interactions.”

IST is a logical partner to assist in the development of the curriculum for the Cell Culture workshop as the company specializes in the testing of clinical trial samples involved in biologics and other immune-based drug research, development and post-market surveillance. IST has decades of experience with biotechnology and diagnostics product development.

“Our program benefits greatly from industrial guidance and involvement,” said Libby Handel, Ph.D., director of the Banner Center for Life Sciences and director of Biotechnology Programs at Palm Beach State College. “IST’s insight is highly valued and will be paramount in the development of curriculum that will be used to educate, and ultimately strengthen Florida’s workforce.”

The Cell Culture Workshop offered on October 27 and 28 is enrolled fully; however, individuals interested in participating in this, or other workshops should contact the Banner Center for registration and fee information. For a schedule of upcoming workshops, please visit http://www.lifesciencesbannercenter.com/TrainingCalendar.

For more information on ImmunoSite Technologies, please visit http://immunositetechnologies.com/; follow IST on Twitter at http://twitter.com/ImmunoSite; or on Facebook at http://www.facebook.com/immunosite.For more information about the Employ Florida Banner Center for Life Sciences, pleasevisit http://www.lifesciencebannercenter.com.

About ImmunoSite Technologies

Formed in 2009 as a spin-off of Beckman Coulter, Inc., ImmunoSite Technologies, LLC (IST) offers a full range of contract research (CRO) for immune monitoring, particle testing, and process automation services for biotechnology, pharmaceutical, manufacturing and academic organizations around the world. Fully GLP compliant and based in Fort Lauderdale, Fla., IST’s team has 110 years of rigorous product development experience, has been published over 300 peer-reviewed scientific publications, has authored over 30 U.S. and international patents, and has developed and successfully commercialized over 200 diagnostic (IVD) product reagents, kits and instrument systems. IST is distinguished by its ongoing partnerships with best-in-class clinical trial organizations such as: the Immune Tolerance Network, the Immune Tolerance Institute, and the Imperial College of London-managed CD4 Initiative. This extensive immune monitoring and cell analysis R&D experience qualifies IST scientists to accelerate vaccine, biologic and drug discovery, and to comply with complex and demanding international scientific and governmental regulations.

About Employ Florida Banner Center for Life Sciences at Palm Beach State College

The Employ Florida Banner Center for Life Sciences at Palm Beach State College is Florida’s industry-driven resource for life sciences workforce education and training throughout the state.  Funded by Workforce Florida, Inc., this consortium of industry, workforce, and educational partners provides training and career advancement solutions for Florida’s life sciences industry, which includes medical devices, pharmaceutical and biotechnology.A resource for all educational institutions, economic development organizations, and regional workforce boards, the Banner Center provides leadership in the ongoing process of developing products and services to increase Florida’s competitiveness in the life sciences industry.

IST Press Contact:

Marketing Matters

Kyle E. Glass, Public Relations/Marketing Manager

Ph: 502-409-5953

Email: kyle@marketingmatters.net

Web: http://www.marketingmatters.net

Banner Center Contact:

Compass Marketing Communications
Carla Brown Lucas, President

Ph: 772-419-0444 (office)

Ph: 772-708-9626 (mobile)

Email:Carla@compassmarcom.com

Web:http://www.compassmarcom.com

Fort Lauderdale, Fla. – April 3, 2011 – ImmunoSite Technologies, LLC, a leading provider of immune monitoring services, is now receiving direct customer referrals for particle testing services from Beckman Coulter, Inc. as part of a recent collaboration agreement.

As part of the agreement, ImmunoSite Technologies (IST) will utilize its extensive industry expertise and experience to perform particle testing for Beckman Coulter customers using Beckman Coulter’s particle testing instrumentation. IST will employ technologies from the “Coulter Principle”, laser diffraction, dynamic light scattering, zeta potential and BET analysis to test all aspects of particulate samples.

IST employs a wide range of technologies to solve all kinds of particle analysis challenges for clients from general chemical and manufacturing to pharmaceutical and cosmetics.

IST and Beckman Coulter particle testing customers benefit from ImmunoSite Technologies’ quick sample-analysis turnaround and superior customer service—including strict confidentially of all data and samples. With 21 CFR part 11 systems available, all samples handled by IST are analyzed with superior methodologies and with the benefit of the latest particle testing technologies and systems. Additionally, all analysis procedures and results data undergo extensive reviews, ensuring that customers receive the best results possible.

ImmunoSite Technologies’ outstanding Good Laboratory Practices (GLP) status was also one of the factors in being selected as a Beckman Coulter partner. IST conducts particle testing for leading companies throughout a wide-range of industries; ranging from pharmaceuticals to various construction materials, cosmetics and more. All protocols for sample handling and data reporting exceed the current GLP standards, reinforcing IST’s commitment to addressing its customer’s requirements for quality control, regulatory compliance and auditing.

“We are extremely confident in the abilities of particle testing and the services we provide to help us solve our customers’ complex problems,” said Wade Bolton, Ph.D., CEO of IST. “This is an important adjunct to our current pharma services in immune monitoring and surveillance.”

For more information on ImmunoSite Technologies, please visit http://immunositetechnologies.com/; follow IST on Twitter at http://twitter.com/ImmunoSite; or follow on Facebook at http://www.facebook.com/pages/ImmunoSite-Technologies-LLC/167604859950599

About ImmunoSite Technologies

Based in Ft. Lauderdale, FL, ImmunoSite Technologies, LLC (IST) offers a full range of contract research (CRO) immune monitoring services to leading biotechnology, pharmaceutical, and academic organizations around the world to provide products and services that span all stages of drug discovery and development. The company is uniquely qualified to develop assays and conduct testing to assess immune status and function. IST is rapidly building a worldwide reputation for services related to qualifying, standardizing, and when appropriate, automating assays associated with cell-mediated immunity. IST services include flow cytometry, particle characterization, application development, automation, assay development and testing. By using qualified reagents, controls, standards and processes, IST-developed functional assays perform within tight specifications and yield reproducible results, helping pharmaceutical and biotechnology companies to accelerate drug discovery, document clinical relevance and reduce costs.

A privately held company, IST was formed in August, 2009, to bring together a highly qualified team of industry leading immune system research and development scientists who together have more than 100 years of experience developing and performing assays related to immune monitoring and surveillance. The IST team has been distinguished by their ongoing partnerships with best-in-class clinical trial organizations such as: the Immune Tolerance Network, the Immune Tolerance Institute, and the Imperial College of London managed CD4 Initiative. This extensive cell analysis R&D experience qualifies IST scientists to comply with complex and demanding international scientific and governmental regulations.

Press Contact: Marketing Matters
Scott Moody, Director of Public Relations
Ph: 954-925-1511
Email: scott@marketingmatters.net
Web: http://www.marketingmatters.net

Link to this release on PRWeb: http://www.prweb.com/releases/2011/04/prweb5219304.htm